Palvella Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wesley H. Kaupinen
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 125 Strafford Avenue Wayne PA United States of America 19087
- IPO Date
- Jan 2, 2015
- CIK
- 0001583648
- Website
- palvellatx.com
- Similar Companies
- Business
- Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapies for patients with serious, rare genetic skin diseases, particularly those lacking FDA-approved treatments. The company’s main product portfolio centers around QTORIN™, a platform of topical treatments that includes QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin. QTORIN™ rapamycin is developed for the treatment of microcystic lymphatic malformations (LMs), cutaneous venous malformations (VMs), and clinically significant angiokeratomas, diseases driven by overactivation of the mTOR pathway. QTORIN™ pitavastatin targets disseminated superficial actinic porokeratosis (DSAP), a rare, chronic, precancerous genetic skin disorder with no approved therapies. The company’s clinical development is advancing with QTORIN™ rapamycin in a Phase 3 SELVA trial for microcystic LMs and a Phase 2 study for cutaneous VMs, with topline results expected in late 2025 and early 2026. Additionally, Palvella plans to initiate a Phase 2 trial for angiokeratomas in 2026. The QTORIN™ pitavastatin candidate was announced in late 2025, marking a significant expansion of the pipeline to address four distinct rare skin diseases. Palvella’s pipeline expansion underscores its strategic focus on rare dermatological conditions with high unmet medical needs. Significant recent corporate developments include the completion of a merger with Pieris Pharmaceuticals in December 2024, which was accompanied by a private placement financing totaling $78.9 million. This capital infusion supports ongoing clinical programs and operations through at least the second half of 2027. The company is simultaneously building out commercial and medical affairs teams in preparation for potential U.S. commercialization in 2027, reflecting a strategic transition towards commercial readiness. Founded in 2015, Palvella Therapeutics is headquartered in Wayne, Pennsylvania, and operates primarily in the United States. Its leadership team has a committed focus on advancing targeted treatments for rare genodermatoses. Palvella’s therapeutic programs leverage proprietary formulations designed to optimize topical delivery of mTOR inhibitors and other agents to affected skin tissues, aiming to offer first-in-class or best-in-class solutions for patients with serious dermatologic conditions. Overall, Palvella Therapeutics operates in the biotechnology sector within the healthcare industry, targeting niche markets of rare skin diseases with unmet clinical needs. The company’s focused product development, recent merger and financing activities, and clinical advancements position it as a clinically promising rare disease biopharmaceutical entity with a growing pipeline of innovative dermatological therapies.
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
Palvella Therapeutics Q1 Earnings Call Highlights
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
Palvella Therapeutics Appoints John D. Doux, M.D.
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $198.07
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting